-
Innovation Ranking
NewInnovation Ranking – VBI Vaccines Inc
VBI Vaccines Inc (VBI), a subsidiary of FDS Pharma LLP is a biopharmaceutical company that discovers and develops novel vaccines in the therapeutic areas of immuno-oncology and infectious diseases. The company’s pipeline vaccine candidates include cytomegalovirus, PreHevbrio, glioblastoma multiforme and zika virus. It utilizes technologies such as eVLP platform, and thermostable platform to develop the vaccine candidates. VBI offers Sci-B-Vac, a hepatitis B vaccine which consists of surface antigens of hepatitis B virus and is free of any next-generation adjuvant....
-
Product Insights
NewNet Present Value Model: Sanofi’s Pneumonia Vaccine
Empower your strategies with our Net Present Value Model: Sanofi's Pneumonia Vaccine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CanSino Biologics Inc’s Pneumococcal Vaccine
Empower your strategies with our Net Present Value Model: CanSino Biologics Inc's Pneumococcal Vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Track & Monitor
Precision and personalized medicine in pharma: personalized cancer vaccines
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s personalized cancer vaccines segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vaccine For Oncology in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vaccine For Oncology in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine For Oncology in Prostate Cancer Drug Details: Plasmodium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vaccine For Oncology in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vaccine For Oncology in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine For Oncology in Ovarian Cancer Drug Details: Plasmodium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vaccine For Insect Allergy in Insect Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vaccine For Insect Allergy in Insect Allergy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine For Insect Allergy in Insect Allergy Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Malaria [strain 7G8] Vaccine in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Malaria [strain 7G8] Vaccine in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Malaria [strain 7G8] Vaccine in Malaria Drug Details: Vaccine candidate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Streptococcus Pneumonia (13-valent) Vaccine in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Streptococcus Pneumonia (13-valent) Vaccine in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Streptococcus Pneumonia (13-valent) Vaccine in Streptococcal Pneumonia Drug Details:...